Our mission is to accelerate the mastery of biology to advance human health. We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology.
The business is unprofitable at the operating level (-9.49% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 5.2%, steady but not accelerating.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$639M
▲ +5.2% YoY
Net Income (TTM)
-$23M
▲ +76.2% YoY
Op. Margin
-6.06%
▲ +22.4pp YoY
ROIC
-3.49%
▲ +13.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$122M
▲ +2371.2% YoY
Op. Cash Flow (TTM)
$128M
▲ +1941.6% YoY
Net Debt
-$458M
Net Cash Position
Cash & Equiv.
$540M
5Y CAGR: +16.6%
Continue Research